<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; MCK</title>
	<atom:link href="http://www.stockbloghub.com/tag/mck/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ABC) AmerisourceBergen Posts Modest Second Quarter Results</title>
		<link>http://www.stockbloghub.com/2012/04/30/abc-amerisourcebergen-posts-modest-second-quarter-results/99760</link>
		<comments>http://www.stockbloghub.com/2012/04/30/abc-amerisourcebergen-posts-modest-second-quarter-results/99760#comments</comments>
		<pubDate>Mon, 30 Apr 2012 18:00:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[ESRX]]></category>
		<category><![CDATA[Express Scripts Inc.]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=99760</guid>
		<description><![CDATA[AmerisourceBergen Corporation (ABC) posted second quarter fiscal 2012 earnings of 81 cents per share, in line with the Zacks Consensus Estimate. However, earnings increased 5.2% from the year-ago period, spurred by higher revenues and a lower share count. Revenues Total revenue for the second quarter edged up 1.6% to $20.1 billion, which were also in line with the Zacks Consensus Estimate. The modest advance in revenues was the result of a 6% increase in AmerisourceBergen Specialty Group’s revenue. The revenue increase for the AmerisourceBergen Specialty Group segment was driven by growth in third party logistics and vaccine and physician office distribution business. The robust performance of AmerisourceBergen Drug Corporation’s institutional segment was offset by the loss of a significant retail customer. TheraCom, a recent acquisition, also contributed toward the quarter’s ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/30/abc-amerisourcebergen-posts-modest-second-quarter-results/99760/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ATHN) Grading the Investment U Gurus 2011: Marc Lichtenfeld</title>
		<link>http://www.stockbloghub.com/2012/01/09/athn-grading-the-investment-u-gurus-2011-marc-lichtenfeld-2/89047</link>
		<comments>http://www.stockbloghub.com/2012/01/09/athn-grading-the-investment-u-gurus-2011-marc-lichtenfeld-2/89047#comments</comments>
		<pubDate>Mon, 09 Jan 2012 16:44:49 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Business Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AINV]]></category>
		<category><![CDATA[Allegheny Technologies Inc]]></category>
		<category><![CDATA[Apollo Investment Corporation]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[Athenahealth Inc]]></category>
		<category><![CDATA[ATHN]]></category>
		<category><![CDATA[ATI]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Capstead Mortgage Corporation]]></category>
		<category><![CDATA[CMO]]></category>
		<category><![CDATA[ESRX]]></category>
		<category><![CDATA[Express Scripts Inc.]]></category>
		<category><![CDATA[FAST]]></category>
		<category><![CDATA[Fastenal Company]]></category>
		<category><![CDATA[Genuine Parts Company]]></category>
		<category><![CDATA[GPC]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[JOE]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[MDP]]></category>
		<category><![CDATA[MedcoHealth Solutions Inc.]]></category>
		<category><![CDATA[Meredith Corporation]]></category>
		<category><![CDATA[MHS]]></category>
		<category><![CDATA[NOC]]></category>
		<category><![CDATA[Northrop Grumman Corporation]]></category>
		<category><![CDATA[Old Republic International Corporation]]></category>
		<category><![CDATA[ORI]]></category>
		<category><![CDATA[The St. Joe Company]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VF Corporation]]></category>
		<category><![CDATA[VFC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89047</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U Senior Analyst Tuesday, December 20, 2011: Issue #1668 I’m excited when my kids bring home their report cards. They’re terrific students, work hard and always bring home good grades. However, it’s always a little nerve-wracking to tabulate my own report card based on my market calls at the end of the year. The market isn’t nearly as forgiving as a second grade teacher. But nevertheless, it’s an important exercise to see what I got right and what I got wrong… what I may have been a little “early” on. So here goes: In my January 14 column, I talked about the rising trend of healthcare information technology and said two of my favorite stocks in the space were AthenaHealth (Nasdaq: ATHN) and McKesson (NYSE: MCK). ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/09/athn-grading-the-investment-u-gurus-2011-marc-lichtenfeld-2/89047/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ATHN) Grading the Investment U Gurus 2011: Marc Lichtenfeld</title>
		<link>http://www.stockbloghub.com/2011/12/21/athn-grading-the-investment-u-gurus-2011-marc-lichtenfeld/88979</link>
		<comments>http://www.stockbloghub.com/2011/12/21/athn-grading-the-investment-u-gurus-2011-marc-lichtenfeld/88979#comments</comments>
		<pubDate>Wed, 21 Dec 2011 17:42:14 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Business Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AINV]]></category>
		<category><![CDATA[Allegheny Technologies Inc]]></category>
		<category><![CDATA[Apollo Investment Corporation]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[Athenahealth Inc]]></category>
		<category><![CDATA[ATHN]]></category>
		<category><![CDATA[ATI]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Capstead Mortgage Corporation]]></category>
		<category><![CDATA[CMO]]></category>
		<category><![CDATA[ESRX]]></category>
		<category><![CDATA[Express Scripts Inc.]]></category>
		<category><![CDATA[FAST]]></category>
		<category><![CDATA[Fastenal Company]]></category>
		<category><![CDATA[Genuine Parts Company]]></category>
		<category><![CDATA[GPC]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[JOE]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[MDP]]></category>
		<category><![CDATA[MedcoHealth Solutions Inc.]]></category>
		<category><![CDATA[Meredith Corporation]]></category>
		<category><![CDATA[MHS]]></category>
		<category><![CDATA[NOC]]></category>
		<category><![CDATA[Northrop Grumman Corporation]]></category>
		<category><![CDATA[Old Republic International Corporation]]></category>
		<category><![CDATA[ORI]]></category>
		<category><![CDATA[The St. Joe Company]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VF Corporation]]></category>
		<category><![CDATA[VFC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88979</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U Senior Analyst Tuesday, December 20, 2011: Issue #1668 I’m excited when my kids bring home their report cards. They’re terrific students, work hard and always bring home good grades. However, it’s always a little nerve-wracking to tabulate my own report card based on my market calls at the end of the year. The market isn’t nearly as forgiving as a second grade teacher. But nevertheless, it’s an important exercise to see what I got right and what I got wrong… what I may have been a little “early” on. So here goes: In my January 14 column, I talked about the rising trend of healthcare information technology and said two of my favorite stocks in the space were AthenaHealth (Nasdaq: ATHN) and McKesson (NYSE: MCK). ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/21/athn-grading-the-investment-u-gurus-2011-marc-lichtenfeld/88979/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OMCL) Omnicell Analyst Reaffirms Shares at Neutral</title>
		<link>http://www.stockbloghub.com/2011/12/14/omcl-omnicell-analyst-reaffirms-shares-at-neutral/87973</link>
		<comments>http://www.stockbloghub.com/2011/12/14/omcl-omnicell-analyst-reaffirms-shares-at-neutral/87973#comments</comments>
		<pubDate>Wed, 14 Dec 2011 20:11:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Computer Based Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87973</guid>
		<description><![CDATA[We recently reiterated our Neutral recommendation on Omnicell (OMCL) with a target price of $17.00. Omnicell reported adjusted EPS of 9 cents in the third quarter of fiscal 2011, beating the Zacks Consensus Estimate by a penny and the year-ago quarter EPS of 4 cents. Revenues in the reported quarter increased 5.6% year over year to $64.4 million and surpassed the Zacks Consensus Estimate of $63 million. The company primarily operates in the niche automated medication distribution industry and stands to benefit from favorable demographic trends, regulatory environments, and the lack of nursing staff. As the information technology market is growing in leaps and bounds with increasing investment by healthcare industries and gradual modernization of the healthcare system, the demand for automated healthcare management systems has also been on the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/14/omcl-omnicell-analyst-reaffirms-shares-at-neutral/87973/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Analyst Maintains Outperform on Shares</title>
		<link>http://www.stockbloghub.com/2011/12/07/cah-cardinal-health-analyst-maintains-outperform-on-shares/88134</link>
		<comments>http://www.stockbloghub.com/2011/12/07/cah-cardinal-health-analyst-maintains-outperform-on-shares/88134#comments</comments>
		<pubDate>Wed, 07 Dec 2011 17:53:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88134</guid>
		<description><![CDATA[We reiterate our Outperform rating on Cardinal Health (CAH). Its first-quarter fiscal 2012 (ended September 30) adjusted earnings per share of 73 cents beat the Zacks Consensus Estimate of 72 cents. Earnings from continuing operations (as reported) dropped about 19% year over year reflecting a previous-year gain from the sale of CareFusion (CFN) shares. Sales for the first quarter rose 10% year over year to $26.8 billion, exceeding the Zacks Consensus Estimate of $26.3 billion. Sales were boosted by growth across the board, notably, buoyancy in the larger Pharmaceutical segment. Revenues from the Pharmaceutical segment spiked 10% year over year in the quarter. Acquisitions contributed to growth as did organic growth from pre-existing clients. Sales from the smaller Medical segment climbed 10%, driven by higher sales to existing and net ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/07/cah-cardinal-health-analyst-maintains-outperform-on-shares/88134/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HSIC) Henry Schein Offers Total Health</title>
		<link>http://www.stockbloghub.com/2011/11/30/hsic-henry-schein-offers-total-health/87820</link>
		<comments>http://www.stockbloghub.com/2011/11/30/hsic-henry-schein-offers-total-health/87820#comments</comments>
		<pubDate>Wed, 30 Nov 2011 20:06:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Medical Equipment Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Henry Schein Inc.]]></category>
		<category><![CDATA[HSIC]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[Patterson Companies Inc.]]></category>
		<category><![CDATA[PDCO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87820</guid>
		<description><![CDATA[Henry Schein (HSIC), a worldwide distributor of healthcare products and services, recently launched its new &#8220;Total Health Beyond the Mouth&#8221; program developed in collaboration with the American Academy for Oral Systemic Health. This new integrated wellness and education program reveals to patients the vital link between oral health and total health, as well as helps out dental professionals in detecting probable systemic health problems, including periodontal disease, oral cancer, sleep disorders, heart disease and diabetes. The Journal of Periodontology notes that an initial investment in preventative periodontal health benefits patients in the long run as severe periodontal disease treatment comes at a much higher price with charges escalating 21% on an average from preventative periodontal health care costs. Henry Schein strongly believes that the Total Health Beyond the Mouth program ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/30/hsic-henry-schein-offers-total-health/87820/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRGE) Merge Healthcare Unveils Cloud-based Platform</title>
		<link>http://www.stockbloghub.com/2011/11/30/mrge-merge-healthcare-unveils-cloud-based-platform/87703</link>
		<comments>http://www.stockbloghub.com/2011/11/30/mrge-merge-healthcare-unveils-cloud-based-platform/87703#comments</comments>
		<pubDate>Wed, 30 Nov 2011 19:58:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare Information Services]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[CMS]]></category>
		<category><![CDATA[CMS Energy Corporation]]></category>
		<category><![CDATA[DELL]]></category>
		<category><![CDATA[Dell Inc.]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[General Electric Company]]></category>
		<category><![CDATA[HIT]]></category>
		<category><![CDATA[Hitachi Limited]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[Merge Healthcare Incorporated.]]></category>
		<category><![CDATA[MRGE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87703</guid>
		<description><![CDATA[Recently, Merge Healthcare (MRGE) showcased its new cloud-based platform ‘Merge Honeycomb’ along with its first application in the cloud, namely ‘free image sharing’ at the Radiological Society of North America (RSNA). This application enables users to upload, download, view and share medical images everywhere without the help of any additional software. Through this new solution the company intends to improve image interoperability and achieve the ‘Meaningful Use’ stamp from the federal government. Earlier this month, Merge selected Dell, Inc (DELL) as its preferred cloud computing services provider. The company expects to launch “Merge Honeycomb” in the first quarter of 2012, which led to a 17.5% increase in the stock price to $5.18 on Monday. Presently, Merge boasts the largest image sharing network opportunity with 6,000 clinics across the US, This ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/30/mrge-merge-healthcare-unveils-cloud-based-platform/87703/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OMCL) Omnicell&#8217;s G4 Platform Reaches China</title>
		<link>http://www.stockbloghub.com/2011/11/30/omcl-omnicells-g4-platform-reaches-china/87704</link>
		<comments>http://www.stockbloghub.com/2011/11/30/omcl-omnicells-g4-platform-reaches-china/87704#comments</comments>
		<pubDate>Wed, 30 Nov 2011 19:57:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Computer Based Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[Gartner Inc.]]></category>
		<category><![CDATA[IT]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87704</guid>
		<description><![CDATA[Recently, Omnicell (OMCL) announced the launch of Mandarin-language versions of its G4 platform for clinical use in China. Following the launch of G4 medication automation platform in English-speaking markets earlier this year, the language conversion of medication cabinets will enable Chinese hospitals to utilize all the advanced operational improvements of G4. The latest move on the company’s part is consistent with its strategy of further expanding in the international market. In China, this system was first implemented at Peking Union Medical College Hospital (PUMCH). A recently completed multi-month pilot study at PUMCH showed that the Omnicell ADCs on Mandarin-language conserve workforce for locating medications by nearly two hours per day. Additionally, Omnicell announced a partnership with China Resources Beijing Pharmaceutical Co. Ltd., which is a subsidiary of China Resources Pharmaceutical ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/30/omcl-omnicells-g4-platform-reaches-china/87704/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OMCL) Omnicell Beats Estimates</title>
		<link>http://www.stockbloghub.com/2011/11/04/omcl-omnicell-beats-estimates/86102</link>
		<comments>http://www.stockbloghub.com/2011/11/04/omcl-omnicell-beats-estimates/86102#comments</comments>
		<pubDate>Fri, 04 Nov 2011 18:57:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Computer Based Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86102</guid>
		<description><![CDATA[Omnicell Inc. (OMCL) reported EPS of 9 cents during the second quarter of fiscal 2011, beating both the Zacks Consensus Estimate of 8 cents and the year-ago quarter EPS of 4 cents. Reported earnings shot up 125% on a year-over-year basis primarily due to the reduction in effective tax rate from 60% in the year-ago quarter to 35% in the reported quarter. Revenues in the reported quarter increased 5.6% year over year to $64.4 million and surpassed the Zacks Consensus Estimate of $63 million. Product revenue, contributing 77.3% of revenues, increased 15.0% to $49.7 million in the quarter while the same from Services and Others (contributing the rest), witnessed an upside of 12.3%. Cost of Product sales were up 13.6% to $22.4 million in the quarter. However, cost of Services ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/04/omcl-omnicell-beats-estimates/86102/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OMCL) Omnicell Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/09/20/omcl-omnicell-analyst-maintains-neutral-on-shares/83310</link>
		<comments>http://www.stockbloghub.com/2011/09/20/omcl-omnicell-analyst-maintains-neutral-on-shares/83310#comments</comments>
		<pubDate>Tue, 20 Sep 2011 20:17:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Computer Based Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83310</guid>
		<description><![CDATA[We recently reiterated our Neutral recommendation on Omnicell (OMCL) with a target price of $16.00. Omnicell reported an adjusted EPS of 8 cents in the second quarter of fiscal 2011, beating both the Zacks Consensus Estimate and the year-ago quarter’s EPS of 6 cents. Total revenue for the second quarter was $61.0 million, up 6.6% year over year and surpassed the Zacks Consensus Estimate of $60.0 million. Product revenue, contributing 75.8% of Omnicell’s top line, increased 8.5% to $46.2 million in the quarter while revenues from Services and Others (contributing the rest), witnessed a marginal upside of 1.4%. The company operates in the niche automated medication distribution industry and stands to benefit from favorable demographic trends, regulatory environments, and the lack of nursing staff. As the information technology market is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/20/omcl-omnicell-analyst-maintains-neutral-on-shares/83310/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HSIC) Henry Schein Extends Reach</title>
		<link>http://www.stockbloghub.com/2011/09/19/hsic-henry-schein-extends-reach/83513</link>
		<comments>http://www.stockbloghub.com/2011/09/19/hsic-henry-schein-extends-reach/83513#comments</comments>
		<pubDate>Mon, 19 Sep 2011 20:21:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Medical Equipment Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Henry Schein Inc.]]></category>
		<category><![CDATA[HSIC]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[Patterson Companies Inc.]]></category>
		<category><![CDATA[PDCO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83513</guid>
		<description><![CDATA[Henry Schein (HSIC), the largest provider of health care products and services to office-based practitioners, recently opened a dental suit for children at Shriners Hospital, Hawaii. The dental suit namely, Dr. Gary I. Kondo Dental Suite will offer treatment to patients from Hawaii as well as the Pacific Rim, regardless of their paying capacity. The Shriners Hospitals for Children includes 22 hospitals nationwide and is a 501(c) 3 non-profit organization. Henry Schein primarily derives its revenue from five divisions:  North American Dental, North American Medical, North American Veterinary, International, and Technology and Value-Added Services. Presently, the company serves more than 700,000 customers worldwide. Henry Schein’s Dental consumable division includes Sullivan-Schein Dental in the US, Henry Schein Arcona in Canada, and the Zahn Dental equipment laboratory supply business in Florida. The ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/19/hsic-henry-schein-extends-reach/83513/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABC) AmerisourceBergen Analyst Reiterates Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/08/26/abc-amerisourcebergen-analyst-reiterates-neutral-on-shares/82113</link>
		<comments>http://www.stockbloghub.com/2011/08/26/abc-amerisourcebergen-analyst-reiterates-neutral-on-shares/82113#comments</comments>
		<pubDate>Fri, 26 Aug 2011 22:29:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[MedcoHealth Solutions Inc.]]></category>
		<category><![CDATA[MHS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82113</guid>
		<description><![CDATA[We recently reiterated our Neutral recommendation on AmerisourceBergen Corporation (ABC) with a target price of $40.00. Over the last several years, the company has been benefiting from the growth of the pharmaceutical industry in the US. We believe AmerisourceBergen should continue to benefit from growth in the pharmaceutical industry, which is driven by several factors like aging population, increased use of generics, introduction of new treatments, increased use of drug therapies and favorable legislative developments. The aforesaid points are continually helping the company, which increased its 2011 earnings guidance range following the release of the third quarter fiscal 2011 financial results. AmerisourceBergen now expects 2011 earnings to lie in the range of $2.52 &#8211; $2.56 per share (previous guidance: $2.41 &#8211; $2.49). We expect fiscal 2011 earnings to increase almost ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/26/abc-amerisourcebergen-analyst-reiterates-neutral-on-shares/82113/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MCK) McKesson Corporation &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/06/28/mck-mckesson-corporation-bull-of-the-day-2/77670</link>
		<comments>http://www.stockbloghub.com/2011/06/28/mck-mckesson-corporation-bull-of-the-day-2/77670#comments</comments>
		<pubDate>Tue, 28 Jun 2011 15:59:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77670</guid>
		<description><![CDATA[McKesson Corp.&#8217;s (MCK) fourth quarter fiscal 2011 earnings of $1.66 per share outpaced the Zacks Consensus Estimate and the year-ago earnings. Revenues climbed 8% to $28.9 billion. McKesson&#8217;s fiscal 2012 guidance was also above expectations. The company expects fiscal 2012 earnings in the range of $5.99 and $6.19 per share. Following the earnings announcement, we raised our 2012 earnings estimate by 50 cents to $6.10. Based on the company&#8217;s performance and guidance, we are upgrading McKesson to Outperform. We believe that the company will continue performing well. Factors like an aging population, increased use of generics and growing demand for specialty pharmaceutical products should help drive growth in the Distribution Solutions segment. We currently have a target price of $100.00 on McKesson. MCKESSON CORP (MCK): Free Stock Analysis Report Zacks ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/28/mck-mckesson-corporation-bull-of-the-day-2/77670/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRGE) Merge&#8217;s Senior Notes Offer Ends</title>
		<link>http://www.stockbloghub.com/2011/06/24/mrge-merges-senior-notes-offer-ends/77321</link>
		<comments>http://www.stockbloghub.com/2011/06/24/mrge-merges-senior-notes-offer-ends/77321#comments</comments>
		<pubDate>Fri, 24 Jun 2011 16:15:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare Information Services]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[General Electric Company]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[Merge Healthcare Incorporated.]]></category>
		<category><![CDATA[MRGE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77321</guid>
		<description><![CDATA[Healthcare information software solutions provider, Merge Healthcare (MRGE) recently completed private offering of $52 million of 11.75% senior secured notes. The company offered the notes as additional debt securities under an indenture in connection to which the company earlier issued $200 million of Senior Secured Notes (due in 2015), supplemented by a supplemental indenture signed on June 14, 2011 related to its previously announced consent solicitation. Merge expects these notes to be guaranteed on a senior basis by all of its domestic restricted subsidiaries.The company plans to utilize the net proceeds of the offering to redeem and retire all of the company’s outstanding Series A Preferred Stock and to pay off all related expenses. Earlier, Merge issued $200 million of 11.75% senior secured notes (due 2015) in April 2010 to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/24/mrge-merges-senior-notes-offer-ends/77321/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OMCL) Omnicell&#8217;s Electronic Health Record Wins Certification</title>
		<link>http://www.stockbloghub.com/2011/06/22/omcl-omnicells-electronic-health-record-wins-certification/77065</link>
		<comments>http://www.stockbloghub.com/2011/06/22/omcl-omnicells-electronic-health-record-wins-certification/77065#comments</comments>
		<pubDate>Wed, 22 Jun 2011 17:01:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Computer Based Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77065</guid>
		<description><![CDATA[Omnicell, Inc. (OMCL), a leading developer and marketer of end-to-end automation solutions for the medication-use process, recently announced that its newly launched G4 platform received the ONC-ATCB certification as a Modular Electronic Health Record (“EHR&#8221;). Omnicell became the first hospital pharmacy automation company to achieve this certification and the company intends to support its clients to qualify for federal funding incentives under the American Recovery and Reinvestment Act (“ARRA”). The Centers for Medicare &#38; Medicaid Services, on May 19, 2011, made the first round of payments totaling $75 million to providers who successfully fulfilled the Stage One requirements for Meaningful Use.  The fulfillment of Meaningful Use criteria is essential for securing federal incentives. EHR automates the process of writing prescriptions and enables the physicians to send prescriptions directly to a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/omcl-omnicells-electronic-health-record-wins-certification/77065/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MCK) McKesson Corporation &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/06/20/mck-mckesson-corporation-bull-of-the-day/76779</link>
		<comments>http://www.stockbloghub.com/2011/06/20/mck-mckesson-corporation-bull-of-the-day/76779#comments</comments>
		<pubDate>Mon, 20 Jun 2011 15:24:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76779</guid>
		<description><![CDATA[McKesson (MCK) reported strong fourth quarter 2011 results with EPS of $1.66, outpacing the Zacks Consensus Estimate and the year-ago earnings. Revenues climbed 8% to $28.9 billion. McKesson&#8217;s fiscal 2012 guidance was also above expectations. The company expects fiscal 2012 earnings in the range of $5.99 and $6.19 per share. Based on the company s performance and the encouraging outlook for fiscal 2012, we are upgrading McKesson to Outperform from Neutral. McKesson is a major player in the pharmaceutical and medical supplies distribution market, and we believe that several factors like an aging population, increased use of generics, and growing demand for specialty pharmaceutical products, especially oncology drugs, should help drive growth in the Distribution Solutions segment. McKesson&#8217;s current trailing 12-month earnings multiple is 15.7, compared with the industry average ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/20/mck-mckesson-corporation-bull-of-the-day/76779/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OMCL) Omnicell  Earns Second Consecutive Best in Klas Award</title>
		<link>http://www.stockbloghub.com/2011/06/19/omcl-omnicell-earns-second-consecutive-best-in-klas-award/76681</link>
		<comments>http://www.stockbloghub.com/2011/06/19/omcl-omnicell-earns-second-consecutive-best-in-klas-award/76681#comments</comments>
		<pubDate>Sun, 19 Jun 2011 17:33:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Computer Based Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76681</guid>
		<description><![CDATA[Omnicell (OMCL), recently announced that it has received recognition for its OmniRx automated dispensing system from leading research firm, KLAS for the second consecutive year.  Along with the  2011 “Best in KLAS&#8221; award for Automated Medication Dispensing Units for large hospitals with more than 200 beds category, Omnicell was also  recognized  as the Category Leader for OmniRx for hospitals under 200 beds. This is the sixth consecutive year that OmniRx has received this KLAS ranking as Category Leader. Omnicell, for the second consecutive year, was adjudged Category Leader for Pharmacy Automation: Medication Carousels for its WorkflowRx Carousel and Category Leader in the new Anesthesia Cabinets award category for Omnicell&#8217;s Anesthesia Workstation. Moreover, Omnicell&#8217;s OmniLinkRx received the Category Leader Distinction for Medication Order Management Systems in Klas’ Software &#38; Professional Services ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/19/omcl-omnicell-earns-second-consecutive-best-in-klas-award/76681/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRGE) Merge Healthcare Issues Senior Notes</title>
		<link>http://www.stockbloghub.com/2011/06/16/mrge-merge-healthcare-issues-senior-notes/76539</link>
		<comments>http://www.stockbloghub.com/2011/06/16/mrge-merge-healthcare-issues-senior-notes/76539#comments</comments>
		<pubDate>Thu, 16 Jun 2011 15:20:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare Information Services]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[General Electric Company]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[Merge Healthcare Incorporated.]]></category>
		<category><![CDATA[MRGE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76539</guid>
		<description><![CDATA[Healthcare information software solutions provider, Merge Healthcare (MRGE) recently announced a private offering of $52 million of 11.75% senior secured notes. The issue price is 103% of the principal amount of the notes, which will mature in 2015. The offer closes on June 14, 2011. Merge offered the notes in two forms. First, as additional debt securities under an indenture pursuant to which Merge earlier issued $200 million of Senior Secured Notes (due in 2015). Second, as supplemented by a supplemental indenture signed on June 14, 2011 related to the company’s previously announced consent solicitation. Merge expects these notes to be guaranteed on a senior basis by all of the company’s domestic restricted subsidiaries. Merge plans to utilize the net proceeds of the offering to redeem and retire all of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/16/mrge-merge-healthcare-issues-senior-notes/76539/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MCK) McKesson Shines &#8211; Provides 2012 View</title>
		<link>http://www.stockbloghub.com/2011/05/04/mck-mckesson-shines-provides-2012-view/73263</link>
		<comments>http://www.stockbloghub.com/2011/05/04/mck-mckesson-shines-provides-2012-view/73263#comments</comments>
		<pubDate>Wed, 04 May 2011 17:36:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73263</guid>
		<description><![CDATA[McKesson Corp.’s (MCK) fourth quarter fiscal 2011 earnings of $1.66 per share (excluding special items) beat the Zacks Consensus Estimate by 6 cents and the year-ago earnings by 40 cents. For fiscal 2011, earnings (excluding special items) came in at $5.00 per share, surpassing the Zacks Consensus Estimate of $4.92 and the previous-year earnings of $4.58 per share. Including expenses associated with the acquisition of US Oncology, earnings for the quarter and the year came in at $1.62 and $4.86 per share, respectively. Higher revenues and lower share count helped boost earnings. Revenues for the fourth quarter climbed 8% to $28.9 billion, marginally beating the Zacks Consensus Estimate of $28.5 billion. Full-year 2011 revenues of $112.1 billion was also ahead of the Zacks Consensus Estimate of $111.7 billion and the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/04/mck-mckesson-shines-provides-2012-view/73263/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Third Quarter 2011 Earnings Preview</title>
		<link>http://www.stockbloghub.com/2011/04/27/cah-cardinal-health-third-quarter-2011-earnings-preview/72565</link>
		<comments>http://www.stockbloghub.com/2011/04/27/cah-cardinal-health-third-quarter-2011-earnings-preview/72565#comments</comments>
		<pubDate>Wed, 27 Apr 2011 17:28:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72565</guid>
		<description><![CDATA[Cardinal Health (CAH) is slated to report its third-quarter fiscal 2011 (ending March) results on Thursday, April 28. The company expects earnings per share in the range of $2.54 to $2.60 for fiscal 2011. The current Zacks Consensus Estimate for revenues and earnings for the third quarter are $25.6 billion and 69 cents per share, respectively. Second Quarter Recap Cardinal Health reported second-quarter fiscal 2011 adjusted earnings per share of 69 cents, beating the Zacks Consensus Estimate of 61 cents and surpassing the year-ago results of 57 cents. Total sales were up 2% year over year to $25.4 billion, beating the Zacks Consensus Estimate. Higher sales from the core Pharmaceutical division were partly offset by a modest decline in the Medical segment. Revenues from the larger Pharmaceutical segment moved up ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/27/cah-cardinal-health-third-quarter-2011-earnings-preview/72565/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/03/17/wpi-watson-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/68917</link>
		<comments>http://www.stockbloghub.com/2011/03/17/wpi-watson-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/68917#comments</comments>
		<pubDate>Thu, 17 Mar 2011 17:02:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Warner Chilcott Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WCRX]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=68917</guid>
		<description><![CDATA[We recently reaffirmed our Neutral stance on Watson Pharmaceuticals Inc. (WPI) following the release of fourth quarter and fiscal year 2010 financial results. Quarterly earnings of 93 cents per share were in line with the Zacks Consensus Estimate and 8 cents above the year-ago earnings. Revenues increased 21.2% to $952.7 million, mainly due to the strong performance of the generics business. Fourth quarter revenues surpassed the Zacks Consensus Estimate of $921 million. For full year 2010, Watson Pharma earned $3.42 per share (up 12.5%) on revenues of $3.6 billion (up 28%). The Zacks Consensus Estimate for 2010 was $3.42 per share on revenues of $3.5 billion. We believe that the company’s cost saving initiative and new product launches, both branded and generic, will help drive growth. We have raised our ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/17/wpi-watson-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/68917/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HIT) Merge Healthcare Announces Seven New Contracts for Clinical Trials</title>
		<link>http://www.stockbloghub.com/2011/02/15/hit-merge-healthcare-announces-seven-new-contracts-for-clinical-trials/66956</link>
		<comments>http://www.stockbloghub.com/2011/02/15/hit-merge-healthcare-announces-seven-new-contracts-for-clinical-trials/66956#comments</comments>
		<pubDate>Tue, 15 Feb 2011 14:53:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Farm & Construction Machinery]]></category>
		<category><![CDATA[Industrial Goods]]></category>
		<category><![CDATA[Claymore-Zacks Country Rotation]]></category>
		<category><![CDATA[CRO]]></category>
		<category><![CDATA[HIT]]></category>
		<category><![CDATA[Hitachi Limited]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[Merge Healthcare Incorporated.]]></category>
		<category><![CDATA[MRGE]]></category>
		<category><![CDATA[RAIT Financial Trust]]></category>
		<category><![CDATA[RAS]]></category>
		<category><![CDATA[SI]]></category>
		<category><![CDATA[Siemens AG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=66956</guid>
		<description><![CDATA[With an aim to strengthen its position in the health IT (HIT) market, Merge Healthcare (MRGE) has taken up seven new contracts for its clinical trials solutions. In this regard, the company signed a deal with North Carolina based Cato Research Ltd., a Contract Research Organization (CRO) which will use Merge’s cost saving solution myEDC for its early phase trials. Merge has started the year with a strong note. In January 2011, its iConnect which is an interoperable platform that enables providers to view current and historical images and content, irrespective of the various ways of image storage, has been selected by Radiology Associates of Sacramento (RAS), North California. Merge is confident about its iConnect platform and expects greater acceptance of the solution going ahead. Also in this month it ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/15/hit-merge-healthcare-announces-seven-new-contracts-for-clinical-trials/66956/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GOOG) Two Stocks Set to Benefit As Healthcare Goes Digital</title>
		<link>http://www.stockbloghub.com/2011/02/02/goog-two-stocks-set-to-benefit-as-healthcare-goes-digital/65192</link>
		<comments>http://www.stockbloghub.com/2011/02/02/goog-two-stocks-set-to-benefit-as-healthcare-goes-digital/65192#comments</comments>
		<pubDate>Wed, 02 Feb 2011 15:11:35 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Internet Information Providers]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Athenahealth Inc]]></category>
		<category><![CDATA[ATHN]]></category>
		<category><![CDATA[GOOG]]></category>
		<category><![CDATA[Google Inc.]]></category>
		<category><![CDATA[IMGN]]></category>
		<category><![CDATA[Immunogen Inc]]></category>
		<category><![CDATA[Lexicon Pharmaceuticals Inc]]></category>
		<category><![CDATA[LXRX]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[Seattle Genetics Inc]]></category>
		<category><![CDATA[SGEN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=65192</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U’s Healthcare Specialist Friday, January 14, 2011: Issue #1428 Editor’s Note: To round off the week, our resident healthcare expert, Marc Lichtenfeld, brings you his second and final report from the J.P. Morgan Healthcare Conference in San Francisco. If you read yesterday’s column, you’ll known that Marc has identified three key trends for the sector this year – one, healthcare reform; two, the “patent cliff” and three… well, take a look below to find out… Talk about an all-star panel of high-tech heavyweights… As I filed into the room, the stage boasted: Aneesh Chopra, the United States’ Chief Technology Officer. Todd Park, Chief Technology Officer at the Department of Health &#38; Human Services. Eric Schmidt, Chairman and CEO of Google (Nasdaq: GOOG). They were there for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/02/goog-two-stocks-set-to-benefit-as-healthcare-goes-digital/65192/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ANR) Company News for February 01, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/02/01/anr-company-news-for-february-01-2011-corporate-summary/66137</link>
		<comments>http://www.stockbloghub.com/2011/02/01/anr-company-news-for-february-01-2011-corporate-summary/66137#comments</comments>
		<pubDate>Tue, 01 Feb 2011 21:04:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[Industrial Metals & Minerals]]></category>
		<category><![CDATA[Alpha Natural Resources Inc]]></category>
		<category><![CDATA[ANR]]></category>
		<category><![CDATA[Cavium Networks Inc.]]></category>
		<category><![CDATA[CAVM]]></category>
		<category><![CDATA[CYT]]></category>
		<category><![CDATA[Cytec Industries Inc.]]></category>
		<category><![CDATA[Exxon Mobil Corporation]]></category>
		<category><![CDATA[INTC]]></category>
		<category><![CDATA[Intel Corporation]]></category>
		<category><![CDATA[Massey Energy Company]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[MEE]]></category>
		<category><![CDATA[PPD]]></category>
		<category><![CDATA[Pre-Paid Legal Services Inc]]></category>
		<category><![CDATA[XOM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=66137</guid>
		<description><![CDATA[• ExxonMobil (NYSE:XOM) reported Q4 EPS of $1.85, ahead of the Zacks Consensus Estimate of $1.68 per share. Revenues for the quarter rose to $105.2 billion, lower than the Zacks Consensus Estimate of $113.268 billion • Alpha Natural Resources (NYSE:ANR) announced a plan to acquire fellow metallurgical coal producer Massey Energy (NYSE:MEE) for $8.5 billion. Massey’s stockholders will receive $10 in cash plus 1.025 shares of Alpha Natural stock for every Massey share. Based on Massey’s Friday closing price of $57.33, the cash and stock deal represents a 21% premium • Intel (NASDAQ:INTC) shares are currently trading 1.03% lower at $21.23 after the company reported it would discontinue production of a computer chip which was found to have a design flaw • Cavium Networks (NASDAQ:CAVM) reported Q4 EPS of $0.29, ex-items, well ahead of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/01/anr-company-news-for-february-01-2011-corporate-summary/66137/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SIGA) These Healthcare Stocks Are Ready to Move Next Week</title>
		<link>http://www.stockbloghub.com/2011/01/07/siga-these-healthcare-stocks-are-ready-to-move-next-week/64553</link>
		<comments>http://www.stockbloghub.com/2011/01/07/siga-these-healthcare-stocks-are-ready-to-move-next-week/64553#comments</comments>
		<pubDate>Fri, 07 Jan 2011 18:11:43 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Athenahealth Inc]]></category>
		<category><![CDATA[ATHN]]></category>
		<category><![CDATA[CGEN]]></category>
		<category><![CDATA[Compugen Limited]]></category>
		<category><![CDATA[DCTH]]></category>
		<category><![CDATA[Delcath Systems Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ESRX]]></category>
		<category><![CDATA[Express Scripts Inc.]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[MedcoHealth Solutions Inc.]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MHS]]></category>
		<category><![CDATA[MOH]]></category>
		<category><![CDATA[Molina Healthcare Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Nektar Therapeutics]]></category>
		<category><![CDATA[NKTR]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[SIGA]]></category>
		<category><![CDATA[SIGA Technologies Inc]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[WellPoint Inc.]]></category>
		<category><![CDATA[WLP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=64553</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U’s Senior Analyst Wednesday, January 5, 2011: Issue #1421 Once again, I’ve secured my golden ticket to the most important healthcare event of the year. In the past, I’ve described the JP Morgan Healthcare Conference as the Super Bowl of the healthcare investing world. That’s no exaggeration either, as industry executives and investors jet in from all over the world to attend. And with hotels, restaurants and even the 37 Starbucks in Union Square packed with people looking for and providing information, even those without an invitation still hit San Francisco just to be near the action. It’s the place to get the latest news on drug development, research funding, and the companies that could be on the cusp of greatness. And for the past few ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/01/07/siga-these-healthcare-stocks-are-ready-to-move-next-week/64553/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Gets Antitrust Clearance</title>
		<link>http://www.stockbloghub.com/2010/12/20/cah-cardinal-health-gets-antitrust-clearance/62814</link>
		<comments>http://www.stockbloghub.com/2010/12/20/cah-cardinal-health-gets-antitrust-clearance/62814#comments</comments>
		<pubDate>Mon, 20 Dec 2010 20:27:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=62814</guid>
		<description><![CDATA[Cardinal Health (CAH) recently announced that antitrust regulators had cleared its $1.3 billion takeover of Kinray, a leading pharma distributor with a presence in the New York metropolitan area. In this regard, the Federal Trade Commission (“FTC”) had approved early termination of waiting period, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, for the planned takeover. The cash deal to acquire Kinray will enhance Cardinal’s capability to cater to retail independent pharmacies in the northeastern U.S. markets. Cardinal expects to shortly close the deal. The company earlier anticipated that the transaction will be neutral to slightly accretive to its fiscal 2011 adjusted earnings, contingent upon the time of the deal closure. Cardinal projects accretion of not less than 12 cents in adjusted earning per share from continuing operations in fiscal ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/20/cah-cardinal-health-gets-antitrust-clearance/62814/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Announces Buy of Kinray</title>
		<link>http://www.stockbloghub.com/2010/12/19/cah-cardinal-health-announces-buy-of-kinray/60379</link>
		<comments>http://www.stockbloghub.com/2010/12/19/cah-cardinal-health-announces-buy-of-kinray/60379#comments</comments>
		<pubDate>Sun, 19 Dec 2010 23:25:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=60379</guid>
		<description><![CDATA[Cardinal Health (CAH) recently announced plans to purchase Kinray Inc., a leading pharma distributor with a presence in the New York metropolitan area. The cash deal will enhance Cardinal’s capability to cater to retail independent pharmacies in the northeastern U.S. markets. Cardinal expects to close the deal by the end of the current calendar year, or early-2011, depending on regulatory approval and closing conditions. The company anticipates that the transaction will be neutral to slightly accretive to its fiscal 2011 adjusted earnings, contingent upon the time of the deal closure. Cardinal projects accretion of not less than 12 cents in adjusted earning per share from continuing operations in fiscal 2012, after taking into account the effect of amortization of intangibles. Kinray is one of the largest privately held distributors of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/19/cah-cardinal-health-announces-buy-of-kinray/60379/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Prepares for Coming Flu Season</title>
		<link>http://www.stockbloghub.com/2010/10/03/cah-cardinal-health-prepares-for-coming-flu-season/53709</link>
		<comments>http://www.stockbloghub.com/2010/10/03/cah-cardinal-health-prepares-for-coming-flu-season/53709#comments</comments>
		<pubDate>Mon, 04 Oct 2010 05:13:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=53709</guid>
		<description><![CDATA[Cardinal Health (CAH) is taking necessary steps to maintain the supply of influenza vaccines during the forthcoming 2010-2011 flu season. For the first time, the Advisory Committee on Immunization Practices (ACIP) has been asking everyone over 6 months of age to get a flu vaccine. The company is of the opinion that the supplies are sufficient to meet the demand as a result of which everybody will have access to the vaccine. There is no need of prioritization. The flu season of last year resulted in more than 270,000 hospitalizations and 12,000 deaths. However, the upcoming season should not be very severe due to the immunity developed from the last infection and availability of the flu vaccine. Moreover, the flu vaccine will target the H1N1 strain in addition to the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/03/cah-cardinal-health-prepares-for-coming-flu-season/53709/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Sells Remaining CareFusion Shares</title>
		<link>http://www.stockbloghub.com/2010/09/19/cah-cardinal-health-sells-remaining-carefusion-shares/52054</link>
		<comments>http://www.stockbloghub.com/2010/09/19/cah-cardinal-health-sells-remaining-carefusion-shares/52054#comments</comments>
		<pubDate>Sun, 19 Sep 2010 17:57:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=52054</guid>
		<description><![CDATA[Cardinal Health (CAH), a leading distributor of pharmaceuticals and medical supplies, recently sold off the remaining 30.5 million shares of CareFusion Corporation (CFN) for $705.9 million. CareFusion, a San Diego-based vendor for medical equipment and infection control supplies, was spun off from Cardinal Health in 2009. As per the spin-off arrangement, Cardinal Health distributed 0.5 shares of CareFusion common stock for each share of its stock that was outstanding. It retained about 19% of the shares in CareFusion at the time of the distribution. Under the terms of the agreement Cardinal Health was required to dispose of its equity holdings in CareFusion within five years of the distribution (by August 31, 2014). The agreement authorized Cardinal to dispose of its shares through open-market sales, private sales or a combination of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/19/cah-cardinal-health-sells-remaining-carefusion-shares/52054/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health and Cumberland Pharmaceuticals Sign Deal</title>
		<link>http://www.stockbloghub.com/2010/08/22/cah-cardinal-health-and-cumberland-pharmaceuticals-sign-deal-2/48444</link>
		<comments>http://www.stockbloghub.com/2010/08/22/cah-cardinal-health-and-cumberland-pharmaceuticals-sign-deal-2/48444#comments</comments>
		<pubDate>Sun, 22 Aug 2010 23:15:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[CPIX]]></category>
		<category><![CDATA[Cumberland Pharmaceuticals]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48444</guid>
		<description><![CDATA[Cardinal Health (CAH), one of the largest distributors of pharmaceuticals and medical supplies, has reportedly inked a distribution agreement with Nashville, Tennessee-based Cumberland Pharmaceuticals (CPIX), a specialty pharmaceutical firm focused on the acute-care hospital and gastroenterology markets. Financial terms of the deal were not divulged by the companies. Under the three-year deal, Cardinal will exclusively distribute three of Cumberland’s drugs in the U.S, Puerto Rico and other specific countries. The drugs covered by the deal are Acetadote, Caldolor and Kristalose. Cumberland will be responsible for delivering these drugs to Cardinal’s distribution center in LaVergne, Tennessee. The deal represents another instance of the long-standing bond between the two companies. Cardinal teamed up with Cumberland in 2002 to market Kristalose (used to treat constipation and hepatic encephalopathy, a brain disorder) in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/22/cah-cardinal-health-and-cumberland-pharmaceuticals-sign-deal-2/48444/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health and Cumberland Pharmaceuticals Sign Deal</title>
		<link>http://www.stockbloghub.com/2010/08/18/cah-cardinal-health-and-cumberland-pharmaceuticals-sign-deal/48250</link>
		<comments>http://www.stockbloghub.com/2010/08/18/cah-cardinal-health-and-cumberland-pharmaceuticals-sign-deal/48250#comments</comments>
		<pubDate>Wed, 18 Aug 2010 18:32:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[CPIX]]></category>
		<category><![CDATA[Cumberland Pharmaceuticals]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48250</guid>
		<description><![CDATA[Cardinal Health (CAH), one of the largest distributors of pharmaceuticals and medical supplies, has reportedly inked a distribution agreement with Nashville, Tennessee-based Cumberland Pharmaceuticals (CPIX), a specialty pharmaceutical firm focused on the acute-care hospital and gastroenterology markets. Financial terms of the deal were not divulged by the companies. Under the three-year deal, Cardinal will exclusively distribute three of Cumberland’s drugs in the U.S, Puerto Rico and other specific countries. The drugs covered by the deal are Acetadote, Caldolor and Kristalose. Cumberland will be responsible for delivering these drugs to Cardinal’s distribution center in LaVergne, Tennessee. The deal represents another instance of the long-standing bond between the two companies. Cardinal teamed up with Cumberland in 2002 to market Kristalose (used to treat constipation and hepatic encephalopathy, a brain disorder) in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/18/cah-cardinal-health-and-cumberland-pharmaceuticals-sign-deal/48250/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Earnings Scorecard</title>
		<link>http://www.stockbloghub.com/2010/08/11/cah-cardinal-health-earnings-scorecard/47655</link>
		<comments>http://www.stockbloghub.com/2010/08/11/cah-cardinal-health-earnings-scorecard/47655#comments</comments>
		<pubDate>Thu, 12 Aug 2010 05:16:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=47655</guid>
		<description><![CDATA[Cardinal Health (CAH), one of the largest distributors of pharmaceuticals and medical supplies, recently reported earnings for fourth-quarter of fiscal year 2010, which beat the Zacks Consensus Estimate by a penny. Revenues grew by a mere 0.5% year over year to $22.3 billion. Pharmaceutical revenues were essentially flat year over year as higher sales to non-bulk customers were offset by lower bulk customer revenues. On a positive note, the company’s generic pharmaceutical business posted a 10% revenue growth in the quarter. The spin-off of CareFusion (CFN) has enabled Cardinal to increase focus on its core healthcare supply chain business. Moreover, Cardinal recently acquired privately held specialty pharmaceutical services company Healthcare Solutions Holding for $667 million. The acquisition has expanded its foothold in the fast-growing specialty pharmaceutical services segment. Agreement – ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/11/cah-cardinal-health-earnings-scorecard/47655/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Analyst Reaffirms Neutral Rating</title>
		<link>http://www.stockbloghub.com/2010/08/10/cah-cardinal-health-analyst-reaffirms-neutral-rating/47468</link>
		<comments>http://www.stockbloghub.com/2010/08/10/cah-cardinal-health-analyst-reaffirms-neutral-rating/47468#comments</comments>
		<pubDate>Wed, 11 Aug 2010 01:34:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=47468</guid>
		<description><![CDATA[We maintain our Neutral recommendation for Cardinal Health (CAH), one of the largest distributors of pharmaceuticals and medical supplies. Earnings for fourth-quarter fiscal 2010 beat the Zacks Consensus Estimate by a penny. However, profit dipped year-over-year, impacted by the spin-off of the company’s non-core Clinical and Medical Products segment (CareFusion), lower customer pricing and supply disruption in the pharmaceutical segment. Revenues grew by a mere 0.5% year-over-year to $22.3 billion, narrowly missing the Zacks Consensus Estimate. Pharmaceutical revenues were essentially flat year-over-year as higher sales to non-bulk customers were offset by lower bulk customer revenues. On a positive note, the company’s generic pharmaceutical business posted a 10% revenue growth in the quarter. Cardinal is one of the largest global healthcare companies that help pharmacies, hospitals and ambulatory care sites to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/10/cah-cardinal-health-analyst-reaffirms-neutral-rating/47468/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ECLP) Eclipsys Glides on Higher Sales</title>
		<link>http://www.stockbloghub.com/2010/08/08/eclp-eclipsys-glides-on-higher-sales/47110</link>
		<comments>http://www.stockbloghub.com/2010/08/08/eclp-eclipsys-glides-on-higher-sales/47110#comments</comments>
		<pubDate>Sun, 08 Aug 2010 16:57:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare Information Services]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[CERN]]></category>
		<category><![CDATA[Cerner Corporation]]></category>
		<category><![CDATA[Eclipsys Corporation]]></category>
		<category><![CDATA[ECLP]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[General Electric Company]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=47110</guid>
		<description><![CDATA[Eclipsys Corporation’s (ECLP) second-quarter fiscal 2010 adjusted earnings of 16 cents per share outshone the Zacks Consensus Estimate of 10 cents while matching the year-ago earnings. Adjusted earnings exclude special items such as restructuring charges, merger costs, amortization and adjustments related to the company’s acquisition of Premise Corporation in 2008. On a reported basis, Eclipsys earned $1.6 million (or 3 cents per share) in the quarter as against a loss of $4.1 million (or 7 cents a share) a year-ago. The turnaround is attributable to higher revenues and lower expenses. Revenues &#38; Bookings Revenues rose 3.5% year-over-year to $134.4 million, but trailed the Zacks Consensus Estimate of $136 million. Revenues from systems and services grew 3% to $125.6 million while hardware sales climbed 36% to roughly $3 million. Revenues from ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/08/eclp-eclipsys-glides-on-higher-sales/47110/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Quarterly Earnings Outperform</title>
		<link>http://www.stockbloghub.com/2010/04/30/cah-cardinal-health-quarterly-earnings-outperform/35762</link>
		<comments>http://www.stockbloghub.com/2010/04/30/cah-cardinal-health-quarterly-earnings-outperform/35762#comments</comments>
		<pubDate>Fri, 30 Apr 2010 15:52:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=35762</guid>
		<description><![CDATA[Cardinal Health, Inc. (CAH) reported third quarter fiscal 2010 earnings per share of 61 cents, outperforming the Zacks Consensus Estimate of 57 cents. However, earnings were lower than the year-ago figure of 66 cents. Sales Total sales in the third quarter increased 1% year over year to $24.3 billion. Growth was witnessed across all business segments. Pharmaceutical segment revenues increased 0.5% year over year to $22.2 billion. Growth was fueled by higher sales to bulk and non-bulk customers. Sales to bulk customers increased 0.5% year over year to $10.9 billion. Sales to non-bulk customers increased 0.5% year over year to $11.3 billion. Medical segment revenues increased 7% year over year to $2.1 billion. Growth can be primarily attributed to higher sales to existing domestic customers and strong performance of the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/30/cah-cardinal-health-quarterly-earnings-outperform/35762/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABC) AmerisourceBergen Beats Forecasts &#8211; Raises Outlook Again</title>
		<link>http://www.stockbloghub.com/2010/04/22/abc-amerisourcebergen-beats-forecasts-raises-outlook-again/34742</link>
		<comments>http://www.stockbloghub.com/2010/04/22/abc-amerisourcebergen-beats-forecasts-raises-outlook-again/34742#comments</comments>
		<pubDate>Thu, 22 Apr 2010 21:32:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34742</guid>
		<description><![CDATA[AmerisourceBergen Corp. (ABC) posted second quarter fiscal 2010 earnings of 63 cents per share, beating the Zacks Consensus Estimate by 8 cents. Earnings increased 34% from the year-ago period. Performance was driven by strong revenues, successful generic drug launches, and continued expense management. Total revenues for the quarter increased 11.5% to $19.3 billion. This was attributable to a 13% growth in AmerisourceBergen Drug Corp. revenues and a 5% rise in Specialty Group revenues. AmerisourceBergen Drug Corp. revenues were driven by new customer additions and overall market growth. New business accounted for more than 4% of revenue growth. Meanwhile, generic revenues remained strong during the quarter. Gross profit for the second quarter was $612.1 million, which reflected an 11% increase over the year-ago period. The improvement was driven by increased revenue ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/22/abc-amerisourcebergen-beats-forecasts-raises-outlook-again/34742/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Beats Expectations and Boosts Estimates</title>
		<link>http://www.stockbloghub.com/2010/01/28/cah-cardinal-health-beats-expectations-and-boosts-estimates/26312</link>
		<comments>http://www.stockbloghub.com/2010/01/28/cah-cardinal-health-beats-expectations-and-boosts-estimates/26312#comments</comments>
		<pubDate>Thu, 28 Jan 2010 20:26:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[ESRX]]></category>
		<category><![CDATA[Express Scripts Inc.]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26312</guid>
		<description><![CDATA[Cardinal Health, Inc. (CAH) reported second quarter fiscal 2010 earnings per share of 57 cents, surpassing the Zacks Consensus Estimate of 46 cents and the year-ago earnings of 51 cents. Sales Total sales in the reported quarter increased 3% year over year to $24.9 billion. Growth was witnessed across all business segments. Pharmaceutical segment revenues increased 3% year over year to $22.7 billion. Growth was primarily fueled by higher sales to existing pharmaceutical distribution customers. Sales to bulk customers declined 1% year over year to $11 billion. Sales to non-bulk customers increased 7% year over year to $11.7 billion. Medical segment revenues increased 9% year over year to $2.2 billion. Growth can be primarily attributed to higher sales to existing customers. Margins Gross and operating margins remained unchanged at 3.8% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/28/cah-cardinal-health-beats-expectations-and-boosts-estimates/26312/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MCK) McKesson Corporation Reports Earnings in Line With Analysts</title>
		<link>http://www.stockbloghub.com/2010/01/27/mck-mckesson-corporation-reports-earnings-in-line-with-analysts/26150</link>
		<comments>http://www.stockbloghub.com/2010/01/27/mck-mckesson-corporation-reports-earnings-in-line-with-analysts/26150#comments</comments>
		<pubDate>Wed, 27 Jan 2010 18:45:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26150</guid>
		<description><![CDATA[McKesson Corp. (MCK) reported fiscal third-quarter earnings of $1.19 per share, in line with the Zacks Consensus Estimate. However, earnings increased 13% from the year-ago profit of $1.05. Meanwhile, revenues increased 4% to $28.3 billion, driven by the strong performance of the Distribution Solutions business. The Distribution Solutions segment grew 4% with the U.S. pharmaceutical distribution business, recording a 2% increase in revenues. The loss of two customer buying groups in the U.S. continued to impact the performance of this segment. We believe the performance of the segment will continue to be impacted by lost business through the remainder of the year. Canadian revenues grew 8%, reflecting market growth. Medical-Surgical distribution revenues also increased (up 11%), benefiting from small acquisitions made by the company in late fiscal 2009 and an ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/27/mck-mckesson-corporation-reports-earnings-in-line-with-analysts/26150/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) The Winners and Losers from a New U.S. Healthcare Reform Bill</title>
		<link>http://www.stockbloghub.com/2009/12/16/pfe-the-winners-and-losers-from-a-new-u-s-healthcare-reform-bill/23025</link>
		<comments>http://www.stockbloghub.com/2009/12/16/pfe-the-winners-and-losers-from-a-new-u-s-healthcare-reform-bill/23025#comments</comments>
		<pubDate>Wed, 16 Dec 2009 22:20:19 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Athenahealth Inc]]></category>
		<category><![CDATA[ATHN]]></category>
		<category><![CDATA[CERN]]></category>
		<category><![CDATA[Cerner Corporation]]></category>
		<category><![CDATA[HUM]]></category>
		<category><![CDATA[Humana Inc.]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[Unitedhealth Group]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23025</guid>
		<description><![CDATA[by Marc Lichtenfeld, Healthcare Expert Wednesday, December 16, 2009: Issue #1159 According to a Thomson Reuters poll, 59.9% of Americans would like to see a public option in any healthcare reform bill, versus just 40% who don’t. If this were an election, it would be a landslide victory. But despite the fact that Main Street actually wants it, the Senate killed the public option in its version of a healthcare reform bill. Business as usual in Washington. But regardless of the current bruhaha in Congress, or the pundits blowing enough hot air to affect the global climate, healthcare reform is most likely coming. Whether or not it will eventually contain a public option remains to be seen. However, Wall Street will likely react negatively to any changes to the system, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/16/pfe-the-winners-and-losers-from-a-new-u-s-healthcare-reform-bill/23025/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MCK) McKesson Beats Estimates &#8211; Raises Guidance</title>
		<link>http://www.stockbloghub.com/2009/10/28/mck-mckesson-beats-estimates-raises-guidance/19071</link>
		<comments>http://www.stockbloghub.com/2009/10/28/mck-mckesson-beats-estimates-raises-guidance/19071#comments</comments>
		<pubDate>Wed, 28 Oct 2009 21:43:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19071</guid>
		<description><![CDATA[McKesson Corp. (MCK) reported its fiscal second-quarter earnings of $1.07 per share, beating the Zacks Consensus Estimate of $1.01. However, earnings declined from the year-ago profit of $1.17. Meanwhile, revenues increased 1.9% to $27.1 billion. The Distribution Solutions segment grew 2% with the U.S. pharmaceutical distribution business recording a 2% increase in revenues. The loss of two customer buying groups in the U.S. continued to impact the performance of this segment. We believe the performance of the Distribution Solutions segment will continue to be impacted by the lost business through the remainder of the year. Canadian revenues grew 9% as the Canadian pharmaceutical market remained slightly stronger than the U.S. market. Medical-Surgical distribution revenues also increased (up 5%), benefiting from small acquisitions made by the company in late fiscal 2009. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/28/mck-mckesson-beats-estimates-raises-guidance/19071/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

